CompletedPHASE1, PHASE2NCT01063907

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Studying Multiple myeloma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kyowa Kirin Co., Ltd.
Principal Investigator
Michael Kurman, MD, PA-C
Kyowa Hakko Kirin Pharma, Inc.
Intervention
KW-2478(drug)
Enrollment
95 enrolled
Eligibility
18 years · All sexes
Timeline
20102013

Study locations (26)

Collaborators

Kyowa Hakko Kirin Pharma, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01063907 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma

← Back to all trials